- Home
- PEBK vs ENTA Comparison
PEBK vs ENTA Comparison
Compare PEBK & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- ENTA
- Stock Information
- Founded
- PEBK 1912
- ENTA 1995
- Country
- PEBK United States
- ENTA United States
- Employees
- PEBK N/A
- ENTA N/A
- Industry
- PEBK Major Banks
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- PEBK Finance
- ENTA Health Care
- Exchange
- PEBK Nasdaq
- ENTA Nasdaq
- Market Cap
- PEBK 169.6M
- ENTA 154.0M
- IPO Year
- PEBK N/A
- ENTA 2013
- Fundamental
- Price
- PEBK $25.72
- ENTA $5.10
- Analyst Decision
- PEBK
- ENTA Buy
- Analyst Count
- PEBK 0
- ENTA 4
- Target Price
- PEBK N/A
- ENTA $17.25
- AVG Volume (30 Days)
- PEBK 8.9K
- ENTA 266.6K
- Earning Date
- PEBK 04-29-2025
- ENTA 05-05-2025
- Dividend Yield
- PEBK 3.53%
- ENTA N/A
- EPS Growth
- PEBK 7.58
- ENTA N/A
- EPS
- PEBK 2.98
- ENTA N/A
- Revenue
- PEBK $82,079,000.00
- ENTA $66,590,999.00
- Revenue This Year
- PEBK N/A
- ENTA N/A
- Revenue Next Year
- PEBK N/A
- ENTA N/A
- P/E Ratio
- PEBK $8.63
- ENTA N/A
- Revenue Growth
- PEBK 7.90
- ENTA N/A
- 52 Week Low
- PEBK $23.74
- ENTA $4.09
- 52 Week High
- PEBK $33.31
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- PEBK 44.11
- ENTA 43.45
- Support Level
- PEBK $25.10
- ENTA $4.55
- Resistance Level
- PEBK $27.10
- ENTA $5.29
- Average True Range (ATR)
- PEBK 1.41
- ENTA 0.47
- MACD
- PEBK -0.03
- ENTA 0.06
- Stochastic Oscillator
- PEBK 41.95
- ENTA 63.96
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh, and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.